JT Stratford LLC’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.75M | Buy |
8,036
+122
| +2% | +$27.1K | 0.22% | 108 |
|
|
2025
Q4 | $1.81M | Sell |
7,914
-5
| -0.1% | -$1.14K | 0.23% | 97 |
|
|
2025
Q3 | $1.83M | Buy |
7,919
+571
| +8% | +$116K | 0.25% | 88 |
|
|
2025
Q2 | $1.36M | Buy |
7,348
+212
| +3% | +$39.4K | 0.21% | 114 |
|
|
2025
Q1 | $1.5M | Buy |
7,136
+88
| +1% | +$17.1K | 0.26% | 94 |
|
|
2024
Q4 | $1.25M | Sell |
7,048
-59
| -0.8% | -$10.8K | 0.21% | 116 |
|
|
2024
Q3 | $1.4M | Buy |
7,107
+536
| +8% | +$100K | 0.24% | 103 |
|
|
2024
Q2 | $1.13M | Buy |
6,571
+276
| +4% | +$45.7K | 0.21% | 121 |
|
|
2024
Q1 | $1.15M | Buy |
6,295
+55
| +0.9% | +$9.48K | 0.23% | 117 |
|
|
2023
Q4 | $967K | Sell |
6,240
-3,676
| -37% | -$536K | 0.22% | 115 |
|
|
2023
Q3 | $1.48M | Buy |
9,916
+1,571
| +19% | +$231K | 0.38% | 67 |
|
|
2023
Q2 | $1.12M | Buy |
8,345
+429
| +5% | +$62.9K | 0.3% | 90 |
|
|
2023
Q1 | $1.26M | Buy |
7,916
+1,144
| +17% | +$175K | 0.36% | 76 |
|
|
2022
Q4 | $1.09M | Buy |
6,772
+153
| +2% | +$23.5K | 0.35% | 78 |
|
|
2022
Q3 | $888K | Sell |
6,619
-519
| -7% | -$74.5K | 0.32% | 75 |
|
|
2022
Q2 | $1.09M | Sell |
7,138
-2,312
| -24% | -$353K | 0.35% | 75 |
|
|
2022
Q1 | $1.53M | Sell |
9,450
-801
| -8% | -$116K | 0.45% | 64 |
|
|
2021
Q4 | $1.39M | Sell |
10,251
-149
| -1% | -$17.6K | 0.38% | 69 |
|
|
2021
Q3 | $1.12M | Sell |
10,400
-49
| -0.5% | -$5.6K | 0.34% | 75 |
|
|
2021
Q2 | $1.18M | Buy |
10,449
+573
| +6% | +$64.5K | 0.38% | 76 |
|
|
2021
Q1 | $1.07M | Buy |
9,876
+1,185
| +14% | +$127K | 0.38% | 69 |
|
|
2020
Q4 | $931K | Sell |
8,691
-46
| -0.5% | -$4.42K | 0.35% | 74 |
|
|
2020
Q3 | $765K | Sell |
8,737
-1,455
| -14% | -$137K | 0.33% | 74 |
|
|
2020
Q2 | $1M | Buy |
10,192
+1,640
| +19% | +$144K | 0.52% | 60 |
|
|
2020
Q1 | $652K | Buy |
8,552
+2,988
| +54% | +$255K | 0.4% | 64 |
|
|
2019
Q4 | $493K | Sell |
5,564
-913
| -14% | -$75.8K | 0.23% | 91 |
|
|
2019
Q3 | $490K | Buy |
6,477
+1,548
| +31% | +$106K | 0.28% | 92 |
|
|
2019
Q2 | $358K | Sell |
4,929
-232
| -4% | -$18.2K | 0.2% | 97 |
|
|
2019
Q1 | $416K | Sell |
5,161
-1,786
| -26% | -$146K | 0.24% | 82 |
|
|
2018
Q4 | $640K | Sell |
6,947
-585
| -8% | -$51.4K | 0.43% | 65 |
|
|
2018
Q3 | $712K | Sell |
7,532
-323
| -4% | -$30.6K | 0.41% | 63 |
|
|
2018
Q2 | $728K | Buy |
7,855
+839
| +12% | +$81.9K | 0.45% | 62 |
|
|
2018
Q1 | $664K | Buy |
7,016
+440
| +7% | +$48.3K | 0.41% | 66 |
|
|
2017
Q4 | $636K | Buy |
6,576
+650
| +11% | +$61.3K | 0.42% | 61 |
|
|
2017
Q3 | $527K | Sell |
5,926
-445
| -7% | -$33.9K | 0.34% | 65 |
|
|
2017
Q2 | $462K | Sell |
6,371
-16,384
| -72% | -$1.1M | 0.33% | 67 |
|
|
2017
Q1 | $1.48M | Sell |
22,755
-10,187
| -31% | -$640K | 1.1% | 35 |
|
|
2016
Q4 | $2.06M | Buy |
+32,942
| New | +$2.01M | 1.73% | 18 |
|
Other funds holding ABBV
VCM
VPM
JT Stratford LLC's ABBV Position: Q1 2026 in Review
JT Stratford LLC increased its AbbVie (ABBV) stake by 1.5% in Q1 2026, buying an estimated $27.1K and bringing the position to 8,036 shares worth $1.75M. The position accounts for 0.22% of the portfolio, ranked #108.
JT Stratford LLC first reported a position in ABBV in Q4 2016 and has held it in 38 quarters since. The position peaked at $2.06M in Q4 2016. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- JT Stratford LLC held 8,036 shares of AbbVie worth $1.75M as of Q1 2026.
- JT Stratford LLC bought 122 AbbVie shares in Q1 2026, an estimated $27.1K.
- AbbVie made up 0.22% of JT Stratford LLC's portfolio in Q1 2026, its #108 holding.
- JT Stratford LLC first reported a position in AbbVie in Q4 2016 and has held it in 38 quarters since.
- JT Stratford LLC's AbbVie position peaked at $2.06M in Q4 2016.
- 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on JT Stratford LLC's 13F filing for Q1 2026, filed 15 May 2026.